| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
iRadimed Corporation$94.49
+0.63 (+0.67%)
Market Cap
1.18 B
EPS
1.85
P/E Ratio
50.17 $
Value Trade
10.08 M
SEC Financials
Q1 2026Dilution Risk
Revenue
21.98 M
R&D Expenses
956.00 K
Operating CF
8.29 M
Total Assets
114.39 M
Total Liabilities
15.88 M
Equity
98.51 M
D/E Ratio
12,345
7.12 %
Week
2.84 %
1 Month
-9.06 %
3 Month
5.26 %
6 Month
219.79 %
5 Year
821 %
All Time
Cash Data
Cash Position
56.37 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 1, 2026
Overview
Volume
79.66 K
52 Week Range
51.26 - 107.90
% held by Insiders
34.87 %
% held by Institutions
60.42 %
Enterprise Value
1.12 B
Total Shares
12.79 M
Short %
8.23 %
Float Shares
8.26 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRMD▲ +0.7%today
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
Iradimed Corporation will announce its second quarter 2026 financial results on July 31, 2026. The company will host a conference call at 11:00 a.m. ET to discuss these results and answer questions. Participants can register for the call and access it online, with a recording available afterward.
Read more →IRMDIRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Iradimed Corporation will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. CEO Roger Susi and CFO Jack Glenn will represent the company, providing investors a chance to schedule one-on-one meetings. Iradimed specializes in MRI-compatible medical devices, including unique IV infusion pumps.
Read more →IRMDIRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for t
IRADIMED CORPORATION reported strong first-quarter financial results for 2026, with revenue of $22 million, a 13% increase from the previous year. The company announced a record GAAP diluted EPS of $0.45, a rise of 22%, alongside a quarterly cash dividend of $0.20 per share. The successful launch of their next-generation MRI-compatible IV infusion pump system has garnered significant early order activity, signaling positive future growth. Looking ahead, the company reaffirmed its full-year guidance for revenue between $91 million and $96 million.
Read more →IRMDIRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
Iradimed Corporation will announce its financial results for the first quarter of 2026 on May 1, 2026, before the market opens. A conference call will follow at 11:00 a.m. ET, where management will discuss the results and answer questions. Interested participants can register online to join the call.
Read more →IRMDIRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
IRADIMED CORPORATION announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 13-16, 2026. CFO Jack Glenn will host one-on-one meetings with investors during the event. The company is recognized for its innovative MRI-compatible medical devices, including the MRidium® IV infusion pump and the 3880 vital signs monitoring system.
Read more →IRMDIRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
Iradimed Corporation will participate in the 38th Annual Roth Conference, scheduled for March 22-24, 2026, at the Ritz-Carlton in Laguna Niguel, CA. CEO Roger Susi and CFO Jack Glenn will host one-on-one meetings with investors. The company is recognized for its MRI-compatible medical devices, including a unique non-magnetic IV infusion pump and a vital signs monitoring system.
Read more →IRMD▲ +9.6%on this news
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
Iradimed Corporation reported record financial results for Q4 and full year 2025, with revenues reaching $22.7 million, a 17% increase from the previous year. The company announced an increase in its quarterly cash dividend to $0.20 per share, reflecting confidence in its business outlook. The rollout of the next-generation MRI-compatible IV infusion pump is expected to begin in Q1 2026, contributing to anticipated revenue growth.
Read more →IRMDIRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
Iradimed Corporation will announce its fourth quarter and full year 2025 financial results on February 10, 2026. A conference call will be held the same day at 11:00 a.m. Eastern Time for discussions and Q&A. Interested participants can register online to receive dial-in details. The call will also be streamed live on the company's website.
Read more →IRMDIRADIMED Announces Special Cash Dividend of $0.50 Per Share
iRadimed Corporation has announced a special cash dividend of $0.50 per share payable on December 30, 2025, to stockholders of record by December 17, 2025. This decision comes after achieving 17 consecutive quarters of record revenue and accumulating $56.5 million in cash. The company is committed to maximizing shareholder returns while continuing to invest in its innovative MRI-compatible medical devices. Future dividends will be determined by the Board based on various financial factors.
Read more →IRMDI R ADIMED Announces Special Cash Dividend of $0.50 Per Share Orlando, Florida
iRadimed Corporation declared a special cash dividend of $0.50 per share, payable on December 30, 2025, to shareholders recorded by December 17, 2025. The company has demonstrated strong financial results, boasting 17 consecutive quarters of record revenue and sufficient cash reserves of $56.5 million. This decision aligns with their commitment to maximizing shareholder returns amidst plans for ongoing investments and a transition to a new manufacturing facility. iRadimed is recognized for its innovative MRI-compatible medical devices, including IV pumps and patient monitoring systems.
Read more →IRMDIRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026
Iradimed Corporation has been named to TIME's list of America's Growth Leaders for 2026, ranking 79th among 501 top U.S. companies. This recognition is based on their outstanding revenue growth, financial health, and stock performance. The company has achieved 17 consecutive quarters of record revenue, showcasing its commitment to innovation and operational excellence.
Read more →IRMD▲ +9.5%on this news
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
Iradimed Corporation reported record financial results for Q3 2025, achieving $21.2 million in revenue, a 16% increase from the previous year. The company maintained a gross margin of 78% and is set to begin limited shipments of its next-generation MRI-compatible IV infusion pump in December 2025. The company raised its full-year revenue guidance to between $82.5 million and $83.5 million.
Read more →IRMDIRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 2025
Iradimed Corporation will announce its third quarter financial results on November 3, 2025, before the market opens. A conference call is scheduled for the same day at 11:00 a.m. ET, where management will discuss the results and answer questions. Interested participants can register online to join the call.
Read more →IRMDIRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires, Joe Kiani Appointed as New Director
Iradimed Corporation announced a transition in its Board of Directors, with Anthony Vuoto retiring and Joe Kiani appointed as a new director. Vuoto has served since 2016, contributing significantly to the company's growth. Kiani, a pioneer in medical technology, is expected to bring valuable expertise to the Board, enhancing Iradimed's mission of delivering MRI-compatible solutions.
Read more →IRMDIRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare Conference
IRADIMED CORPORATION will participate in the 2025 Wells Fargo Healthcare Conference from September 3-5, 2025, in Boston. CEO Roger Susi and CFO Jack Glenn will host one-on-one investor meetings on September 4. The conference is a significant event for healthcare companies and investors to discuss innovations and investment opportunities.
Read more →IRMD▲ +13.4%on this news
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 m
IRADIMED CORPORATION reported record financial results for Q2 2025, registering a revenue of $20.4 million, marking a 14% increase compared to the previous year. The company also announced a regular quarterly cash dividend of $0.17 per share and raised its full-year revenue and earnings guidance. Despite expressing a strong outlook for continued growth, management cautions about potential operational inefficiencies in the upcoming third quarter as they transition into a new facility.
Read more →IRMDIRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025
IRADIMED CORPORATION announced it will release its second quarter financial results on August 1, 2025, before the market opens. A conference call is scheduled for the same day at 11:00 AM Eastern Time to discuss the results. Interested participants can register to join the call and access it online. The company highlights its leadership in developing MRI-compatible medical devices, including non-magnetic infusion pumps that improve safety during MRI procedures.
Read more →IRMD▲ +12.5%on this news
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
Iradimed Corporation has received FDA 510(k) clearance for its MRidium® 3870 IV Infusion Pump System, marking a significant advancement in MRI-compatible medical technology. This system features a non-magnetic design, advanced safety features, and an intuitive interface, enhancing patient care during MRI procedures. The rollout is planned for late 2025, with full distribution expected in 2026.
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2025 Financial Results
Iradimed Corporation reported its financial results for Q1 2025, achieving record revenue of $19.5 million, an 11% increase from the previous year. The company reaffirmed its full-year revenue and earnings guidance, expecting to generate between $78 million and $82 million. A quarterly cash dividend of $0.17 per share was also announced, emphasizing its commitment to shareholder returns.
Read more →IRMDCORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
IRADIMED CORPORATION has corrected the date for its first quarter 2025 financial results conference call to May 5, 2025. The company will release its financial results before the market opens, followed by a conference call at 9:00 a.m. ET. Participants can register online to join the call, which will also be available for later listening on the company's website.
Read more →IRMDIRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
IRADIMED CORPORATION will release its financial results for the first quarter of 2025 before the market opens on May 5, 2025. A conference call will take place on the same day at 9:00 a.m. ET for discussion of these results and to address questions. Interested participants can register online to receive the call details, and an internet stream of the call will also be available. IRADIMED is recognized for its MRI-compatible medical devices, enhancing safety and care for patients during MRI procedures.
Read more →IRMDIRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
IRADIMED CORPORATION announced its participation in the 37th Annual Roth Conference, scheduled for March 17 and 18, 2025, in Dana Point, CA. CFO Jack Glenn and CCO Jeff Chiprin will lead one-on-one meetings with investors at this event, which showcases the company's innovative MRI-compatible medical devices. As a leader in this niche, IRADIMED focuses on developing safe IV infusion systems and vital signs monitoring solutions for use during MRI procedures. This engagement at the conference is expected to enhance investor relations and market presence.
Read more →IRMD▼ -8.4%on this news
IRADIMED CORPORATION Announces Fourth Quarter and Full Year of 2024 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.17 Per Share from $0.15 Per Share Reports record revenue of $19.4 million for
IRADIMED CORPORATION announced its financial results for Q4 and the full year of 2024, reporting record revenues of $19.4 million and net income of $5.1 million, reflecting successful growth. The company has declared an increase in its quarterly cash dividend to $0.17 per share, highlighting its strong financial position amid robust demand for its MRI-compatible products. The annual revenue reached $73.2 million, with an expectation to generate between $78.0 million and $82.0 million in 2025, indicating continued positive momentum. Additionally, construction on a new facility is ahead of schedule, providing further capacity for growth.
Read more →IRMDIRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
IRADIMED Corporation has announced that it will release its fourth quarter and full year 2024 financial results before the market opens on February 13, 2025. Following the release, management will host a conference call to discuss the results in detail and answer questions from investors. The conference call is accessible via registration and will also be streamed online. As a leader in MRI-compatible medical devices, IRADIMED emphasizes the safety and reliability of its innovative product offerings.
Read more →IRMDIRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports pr
iRadimed Corporation reported preliminary unaudited revenues for the fourth quarter and full-year 2024, signaling significant growth over the previous year. The company expects fourth-quarter revenues of approximately $19.2 million to $19.4 million, along with full-year revenues anticipated between $73.1 million and $73.3 million. This marks a year-over-year growth of around 11% to 12%. iRadimed also noted a backlog of orders as they prepare for their upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
Read more →IRMDIRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
IRADIMED Corporation is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will feature insights from CEO Roger Susi and CFO Jack Glenn. The company specializes in MRI-compatible medical devices, notably its innovative IV infusion pump system designed to ensure patient safety during MRI procedures. Interested parties can access the presentation via the company's investor website.
Read more →IRMDIRADIMED CORPORATION on Forbes’ List of America’s Most Successful Small-Cap Companies for 2025
Iradimed Corporation has been ranked 24th on Forbes' List of America’s Most Successful Small-Cap Companies for 2025, an improvement from last year's 59th position. This recognition is attributed to the company's pioneer work in developing MRI-compatible medical devices and a commitment to innovation. CEO Roger Susi highlighted the achievement as a testament to the company's growth, strategic execution, and the dedication of its team. Iradimed's focus on enhancing patient safety through non-magnetic medical devices sets it apart in the industry.
Read more →IRMDIRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024
IRADIMED CORPORATION has been recognized by Fortune as one of the 100 Fastest Growing Companies for 2024, earning the 61st spot on the prestigious list. The ranking reflects the company's impressive growth in revenue, profits, and stock returns. As a leader in MRI-compatible medical devices, Iradimed is poised to further enhance patient safety while pursuing impactful growth strategies. This recognition underscores their team's dedication to innovation and delivering valuable medical equipment.
Read more →IRMD▼ -6.9%on this newsshared move
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $18.3 million for the third quarter of 2024,
IRADIMED CORPORATION has announced financial results for the third quarter of 2024, reporting record revenue of $18.3 million, an 11% increase compared to the same quarter in the previous year. The company declared a quarterly cash dividend of $0.15 per share and raised its earnings guidance for the upcoming fourth quarter. Confidence in continued growth is supported by robust domestic sales of its IV infusion pump systems. The company anticipates fourth-quarter revenue between $18.8 million and $19.2 million, showcasing ongoing positive momentum.
Read more →IRMDIRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
IRADIMED Corporation announced that it will release its 2024 third quarter financial results on October 31, 2024, before the market opens. Management will host a conference call at 11:00 a.m. ET on the same day to discuss the results and answer questions. Interested participants can register for the call online, and a recording will be made available on the company's website afterward. IRADIMED is recognized for its MRI-compatible medical devices, highlighting its innovative approach to patient safety during MRI procedures.
Read more →IRMDIRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Iradimed Corporation (NASDAQ: IRMD) has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference where CFO Jack Glenn will engage in one-on-one meetings with investors. The conference is scheduled to take place on October 9, 2024, at the Metropolitan Club in New York. Iradimed is noted for its innovative MRI-compatible medical devices, including a non-magnetic IV infusion pump system designed for safe use during MRI procedures. The company aims to enhance patient safety and improve monitoring during critical care.
Read more →IRMDIRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the Lake Street 8th Annual Best Ideas Growth 'Big 8' Conference, scheduled for September 12, 2024. The event will include one-on-one meetings between the company's management and investors, which presents an opportunity to discuss their innovative MRI-compatible medical devices. Iradimed is known for its leading MRidium® IV infusion pump system and the 3880 MRI-compatible vital signs monitoring system, both designed for safety during MRI procedures.
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $17.9 million for the second quarter of 2024
IRADIMED CORPORATION reported its financial results for the second quarter of 2024, achieving record revenue of $17.9 million, an 11.2% increase over the previous year. The company also declared a quarterly cash dividend of $0.15 per share, payable at the end of August. Continued growth in its IV infusion pump line contributed to a significant rise in both revenue and net income, which reached $4.9 million for the quarter, up 17.3% year-over-year. The company anticipates maintaining strong performance in the second half of the year with projected revenues between $72.0 million and $74.0 million.
Read more →IRMDIRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
IRADIMED CORPORATION is set to release its 2024 second quarter financial results on August 1, 2024, before the market opens. Management will host a conference call at noon to discuss the results and field questions from participants. Interested individuals are encouraged to register online to participate in the call, which will also be available via a real-time internet stream and a recording on the company's website afterward.
Read more →IRMDIRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market Trading to commence effective on the market open
Iradimed Corporation has announced its uplisting to the Nasdaq Global Market, effective June 14, 2024. This transition from the Nasdaq Capital Market highlights the company's growth and commitment to delivering value to its shareholders. The uplisting is not only a significant milestone but also increases Iradimed's visibility in the market, positioning it to attract potential new investors. The company's focus on innovative MRI-compatible medical devices continues to drive its success in the medical device sector.
Read more →IRMDAMENDMENT TO SUSI, LLC LEASE AGREEMENT TIDS AMENDMENT TO SUSI, LLC LEASE AGREEMENT (this "Amendment") is made
IRadimed Corporation has amended its lease agreement with SUSI, LLC effective May 29, 2024. The agreement involves a consideration of ten dollars as part of this modification. Both parties have acknowledged the receipt and sufficiency of this consideration. The amendment indicates a formal recognition of changes made to their leasing arrangements.
Read more →IRMDIRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $17.6 million for the first quarter of 2024.
Iradimed Corporation announced its financial results for the first quarter of 2024, reporting record revenue of $17.6 million, marking the eleventh consecutive quarter of revenue growth. The company's net income increased by 21.4% to $4.1 million, driven primarily by their monitoring product line and strong pump orders. The company anticipates continued revenue growth and has declared a quarterly cash dividend of $0.15 per share, reaffirming positive financial expectations for the upcoming quarters.
Read more →IRMDIRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd
Iradimed Corporation (NASDAQ: IRMD) has announced it will release its financial results for the first quarter of 2024 on May 2nd before the market opens. Following the announcement, management will host a conference call at 11:00 a.m. Eastern Time to discuss the results. Interested participants can register online to join the call, which will also be available for live streaming and recording on the company's website. Iradimed is recognized for its innovative MRI-compatible medical devices, enhancing patient safety during MRI procedures.
Read more →IRMDIRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
IRADIMED Corporation is set to participate in the 36th Annual Roth Conference, where CEO Roger Susi will have a live fireside chat. This event, scheduled for March 19, aims to bring together around 500 growth-oriented private and public companies. The conference will feature a range of activities including small group meetings, thematic panels, and presentations by executives. IRADIMED is recognized for its development of MRI-compatible medical devices that enhance patient safety during MRI procedures.
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP dilut
IRADIMED CORPORATION announced strong financial results for the fourth quarter and full year of 2023, with record revenue of $17.5 million in Q4, up from $14.9 million in Q4 2022. The company reported a net income of $4.5 million for the fourth quarter, leading to a total annual revenue of $65.6 million, a significant increase from $53.3 million in 2022. Iradimed's growth is attributed to demand for its IV infusion pumps and monitoring systems, as well as the anticipation of a quarterly dividend starting in 2024. The company projects continued revenue growth for 2024, with guidance of $72.0 million to $74.0 million.
Read more →IRMDIRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
Iradimed Corporation has announced that it will release its 2023 fourth quarter financial results on February 8, 2024, before the market opens. Following the release, management will host a conference call at 9:00 a.m. Eastern Time to discuss the results and engage with participants. The company is recognized for its innovative MRI-compatible medical devices, especially its MRidium® IV infusion pump system and 3880 patient vital signs monitoring system.
Read more →IRMDIRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
IRADIMED CORPORATION reported its unaudited revenue results for the fourth quarter and the fiscal year 2023, highlighting a revenue of approximately $17.5 million in Q4 and around $65.6 million for the entire year, marking a 23% increase from the previous year. This performance represents the highest quarterly revenue in the company's history and extends a streak of ten consecutive quarters of record revenues. CEO Roger Susi expressed confidence in continued demand for their MRI-compatible medical devices into 2024.
Read more →IRMDIRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
Iradimed Corporation will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company specializes in innovative MRI-compatible medical devices and aims to highlight its unique offerings, including a non-magnetic IV infusion pump and an MRI-compatible vital signs monitoring system. The presentation will be accessible via a live and archived webcast for interested stakeholders.
Read more →IRMDI R ADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share Winter Springs, Florida
IRADIMED CORPORATION has announced a special cash dividend of $0.48 per share and initiated a regular quarterly dividend of $0.15 per share, reflecting its strong financial performance. Both dividends are payable on January 12, 2024, to shareholders of record as of December 22, 2023. The company is also planning a $20 million expansion of its production facilities to support anticipated growth. This follows the previous payment of special dividends in prior years, emphasizing their commitment to return cash to shareholders.
Read more →IRMDIRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share
Iradimed Corporation has announced the establishment of a quarterly dividend of $0.15 per share and a special cash dividend of $0.48 per share, reflecting the company's strong financial performance. Both dividends are payable on January 12, 2024, to shareholders of record as of December 22, 2023. The company is also planning to expand its production capacity with a project estimated at $20 million, which may be funded through available cash or financing. This move demonstrates Iradimed's commitment to returning value to shareholders while positioning itself for future growth.
Read more →IRMDIRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes
IRADIMED CORPORATION has been recognized by Forbes as one of America's Most Successful Small-Cap Companies for 2024. This accolade highlights the company's significant sales growth and exceptional performance metrics over the past year. The recognition focuses on IRADIMED's innovative MRI-compatible medical devices, including its non-magnetic IV infusion pump system and vital signs monitoring systems. CEO Roger Susi expressed pride in the team's efforts and emphasized a commitment to continuing their success in the healthcare market.
Read more →IRMD▲ +9.9%on this news
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results Reports record revenue of $16.5 million for the third quarter of 2023. GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43. Third quarter operat
Iradimed Corporation announced significant financial results for Q3 2023, reporting record revenues of $16.5 million, a 23% increase year-over-year. The company's net income rose to $5.1 million, or $0.40 per diluted share, reflecting strong performance in its monitoring business. Iradimed has raised its guidance for the fourth quarter and full year, expecting to achieve revenues between $16.9 million to $17.4 million for Q4 2023 and a total revenue of $65.0 million to $65.5 million for the year. This continued growth underscores the company's leadership in MRI-compatible medical devices.
Read more →IRMDIRADIMED CORPORATION to Hold 2023 Third Quarter Financial Results Conference Call on November 3rd
IRADIMED CORPORATION has announced that it will release its 2023 third quarter financial results on November 3rd before market open. A conference call is scheduled for the same day at 11:00 a.m. Eastern Time, where management will discuss the results and answer questions. The call is accessible to registered participants, and a recording will be available on the company's website after the event. The corporation is known for its innovative MRI-compatible medical devices aimed at improving patient care during MRI procedures.
Read more →IRMDIRADIMED CORPORATION to Participate at Upcoming Investor Conferences
IRADIMED CORPORATION announced its participation in two upcoming investor conferences, emphasizing its commitment to engaging with the investment community. The conferences are the H.C. Wainwright 25th Annual Global Investment Conference and the Lake St. Capital 7th Annual Best Ideas Growth Conference, both taking place in New York City. The company is recognized for its innovative MRI-compatible medical devices, including its non-magnetic IV infusion pump and vital signs monitoring system designed for safe operation during MRI procedures.
Read more →IRMD▲ +10.2%on this news
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results Reports record revenue of $16.1 million for the second quarter of 2023 GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36 Operating income was
IRADIMED CORPORATION announced its financial results for the second quarter of 2023, reporting record revenue of $16.1 million, representing a 25% year-over-year growth. The company achieved net income of $4.2 million, or $0.33 per diluted share, while non-GAAP diluted earnings per share reached $0.36. Due to increasing demand, IRADIMED has raised its full-year revenue guidance, expecting earnings of between $64.5 million and $65.5 million. This marks the eighth consecutive quarter of record revenue for the company.
Read more →IRMD▼ -5.4%on this news
IRADIMED CORPORATION to Hold 2023 Second Quarter Financial Results Conference Call on August 3rd
IRADIMED CORPORATION is set to release its financial results for the second quarter of 2023 before the market opens on August 3rd. A conference call will take place on the same day at 11:00 a.m. Eastern Time, where management will discuss the results and answer questions from participants. The company is known for its innovative MRI-compatible medical devices, including a unique IV infusion pump system designed to ensure patient safety during MRI procedures.
Read more →IRMDIRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes Winter Springs, Florida
IRADIMED CORPORATION has been named one of America's Best Small Companies for 2023 by Forbes, highlighting its position as a leader in MRI-compatible medical devices. Forbes selected the company based on criteria including sales growth, earnings growth, and total stock return over the last five years. The company is particularly noted for its non-magnetic intravenous infusion pumps and patient vital signs monitoring systems designed specifically for MRI procedures. CEO Roger Susi has expressed pride in this recognition, attributing it to the hard work of the team and the support of customers and shareholders.
Read more →IRMD▲ +7.1%on this news
IRADIMED CORPORATION Announces First Quarter 2023 Financial Results Reports record revenue of $15.5 million for the first-quarter quarter of 2023 GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30 Operating inco
IRADIMED CORPORATION reported its first quarter 2023 financial results, highlighting a record revenue of $15.5 million, a notable increase of over 25% from the previous year. This marks the company's highest revenue quarter and continues a trend of record revenues for seven consecutive quarters. The net income also saw an increase, reflecting solid operational performance. Additionally, the company declared a special dividend of $1.05 per share and raised its full-year revenue outlook to between $62 million and $63.5 million.
Read more →IRMDIRADIMED CORPORATION to Hold 2023 First Quarter Financial Results Conference Call on May 4th
Iradimed Corporation (NASDAQ: IRMD) is set to release its first quarter financial results on May 4, 2023, before the market opens. Following the announcement, management will conduct a conference call at 11:00 a.m. Eastern Time to discuss the results and address questions from participants. Interested individuals can register for the conference call and access a recording afterward on the company's website. Iradimed is recognized for its specialized MRI-compatible medical devices that prioritize patient safety.
Read more →IRMDIRADIMED CORPORATION To Present at the 35th Annual Roth Conference
IRADIMED CORPORATION will present at the 35th Annual Roth Conference in Laguna Niguel, CA, with CEO Roger Susi scheduled for a live fireside chat. The conference includes meetings and presentations from about 400 companies in various sectors. This event serves as a platform for IRADIMED to showcase its MRI-compatible medical devices, positioning the company for increased investor engagement.
Read more →IRMDIRADIMED CORPORATION Issues Urgent Medical Device Correction
Iradimed Corporation issued an Urgent Medical Device Correction Letter addressing a potential issue with its 1057 Syringe Adapter Set, which may cause reduced flow during use with the MRidium infusion pump. The company received five complaints related to an unexpected inlet occlusion alarm, though none resulted in injuries. The correction aims to maximize safety, and Iradimed does not expect a financial impact from this action. No other IV sets from the company are affected.
Read more →IRMD▲ +12.5%on this news
IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted
IRADIMED CORPORATION announced its fourth quarter and full year 2022 financial results, showing strong revenue growth. The company reported $14.9 million in revenue for Q4 2022, marking an increase from the previous year, and declared a special cash dividend of $1.05 per share. However, net income saw a slight decline due to higher income taxes. The company continues to maintain a solid cash position with no debt and projects further growth in revenue and earnings for 2023.
Read more →IRMDIRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd
IRADIMED Corporation announced it will release its fourth quarter financial results on February 2, 2023, prior to market opening. A conference call will take place at 11:00 AM Eastern Time on the same day, allowing management to discuss the results and address questions from stakeholders. This transparency in financial reporting can be seen as a positive sign of the company's commitment to its investors.
Read more →IRMD▲ +9.1%on this news
IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022 Reports preliminary fourth quarter 2022 revenue of $14.9 million Announces full-year and first-quarter 2023 financial guidance Winter S
iRadimed Corporation announced its preliminary financial results for the fourth quarter of 2022, reporting a revenue of approximately $14.9 million, up 25% year-over-year. This figure exceeds their previous guidance and marks their highest quarterly revenue ever. The company has consistently achieved record revenues for six quarters in a row and anticipates continued growth into 2023, with expected revenue between $61 million and $63 million for the full year. The results reflect the growing demand for the company’s MRI-compatible medical devices and accessories.
Read more →IRMD▲ +6.7%on this news
I R ADIMED CORPORATION Announces Third Quarter 2022 Financial Results Revenue was $13.4 million and increased by 23% Operating income was $4.1 million and increased by 32% GAAP diluted EPS was $0.27 and increased by 35%
CORPORATION Announces Third Quarter 2022 Financial Results Winter Springs, Florida, November 3, 2022 - IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2022. The Company is a leader in th
Read more →IRMD▲ +6.7%on this news
IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results
Revenue was $13.4 million and increased by 23% Operating income was $4.1 million and increased 32% GAAP diluted EPS was $0.27 and increased by 35% Announces fourth quarter 2022 financial guidance WINTER SPRINGS, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (th
Read more →IRMDIRADIMED CORPORATION to Hold 2022 Third Quarter Financial Results Conference Call on November 3rd
WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 third quarter financial results before the market opens on Thursday, November 3rd. IRADIMED management will host a conference call th
Read more →IRMDIRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA Announces Preliminary Financial Results for Third Quarter 2022 Winter Springs, Florida
IRADIMED CORPORATION Withdraws 510(k) with Plans to Further Discussions with FDA Announces Preliminary Financial Results for Third Quarter 2022 Winter Springs, Florida, October 10, 2022 - iRadimed Corporation (the "Company") (NASDAQ: IRMD) today announced that the Company, aft
Read more →IRMDIRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors Winter Springs, Florida
IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors Winter Springs, Florida, October 6, 2022 - iRadimed Corporation (the "Company") (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors,
Read more →IRMD▲ +6.9%on this news
IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results Reports second quarter 2022 revenue of $12.7 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.26 Announces third quarter 2022 financia
IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results Winter Springs, Florida, July 29, 2022 - IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2022. The Company is a leader in
Read more →IRMDIRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the sa
Read more →IRMDI R ADIMED Names John F. Glenn Chief Financial Officer Winter Springs, Florida
IRADIMED Names John F. Glenn Chief Financial Officer Winter Springs, Florida, May 26, 2022 - iRadimed Corporation (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume respons
Read more →IRMDIRADIMED Names John F. Glenn Chief Financial Officer
WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume responsibility for all areas of accounting and
Read more →IRMD▼ -20.1%on this news
I RADIMED CORPORATION Announces First Quarter 2022 Financial Results Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22 Announces second quarter 2022 financia
CORPORATION Announces First Quarter 2022 Financial Results Winter Springs, Florida, April 29, 2022 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022. The Company is a leader in the development
Read more →IRMD▼ -20.1%on this news
IRADIMED CORPORATION Announces First Quarter 2022 Financial Results
Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22 Announces second quarter 2022 financial guidance Increases full-year 2022 financial guidance WINTER SPRINGS, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPO
Read more →IRMDIRADIMED CORPORATION Announces Executive Transition
WINTER SPRINGS, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resigned from the Company effective May 27, 2022. Mr. Scott started at the Company
Read more →IRMDIRADIMED CORPORATION Executive Transition Winter Springs, Florida
IRADIMED CORPORATION Executive Transition Winter Springs, Florida, April 28, 2022 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resigned from the Company effective May 27, 2022. Mr.
Read more →IRMDIRADIMED CORPORATION to Hold 2022 First Quarter Financial Results Conference Call on April 29th
WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April 29th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED Announces Special $1.00 Per Share Cash Dividend Winter Springs, Florida
IRADIMED Announces Special $1.00 Per Share Cash Dividend Winter Springs, Florida, February 7, 2022 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company's outstanding comm
Read more →IRMD▲ +23.7%on this newsshared move
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33 Announces full-year and first quarter
CORPORATION Announces Fourth Quarter 2021 Financial Results Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33 Announces full-year and first quarter 2022 financial guidance Winter Springs, Florida, February 4, 2
Read more →IRMDIRADIMED CORPORATION to Hold 2021 Fourth Quarter Financial Results Conference Call on February 4th
WINTER SPRINGS, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 fourth quarter financial results before the market opens on Friday, February 4th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2021 Financial Results Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Increases full-year 2021 financial guid
CORPORATION Announces Third Quarter 2021 Financial Results Winter Springs, Florida, October 29, 2021 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider
Read more →IRMDIRADIMED CORPORATION to Hold 2021 Third Quarter Financial Results Conference Call on October 29th
WINTER SPRINGS, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens on Friday, October 29th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2021 Financial Results
Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14 Issues Q3 and full year 2021 financial guidance WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2021 Financial Results Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14 Issues Q3 and full year 2021 financia
CORPORATION Announces Second Quarter 2021 Financial Results Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14 Issues Q3 and full year 2021 financial guidance Winter Springs, Florida, July 30, 2021 - iRadimed Co
Read more →IRMDIRADIMED CORPORATION to Hold 2021 Second Quarter Financial Results Conference Call on July 30th
WINTER SPRINGS, Fla., July 07, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 second quarter financial results before the market opens on Friday, July 30th. IRADIMED management will host a conference call the sa
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2021 Financial Results
Reports first quarter 2021 revenue of $9.2 million, GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.13 Reports combined cash and investments of $52.7 million as of March 31, 2021 WINTER SPRINGS, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Compan
Read more →IRMDI RADIMED CORPORATION Announces First Quarter 2021 Financial Results Reports first quarter 2021 revenue of $9.2 million, GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.13 Reports combined cash and investments o
CORPORATION Announces First Quarter 2021 Financial Results Winter Springs, Florida, April 30, 2021 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of
Read more →IRMDIRADIMED CORPORATION to Hold 2021 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 09, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 first quarter financial results before the market opens on Friday, April 30th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results Reports fourth quarter 2020 revenue of $8.5 million, GAAP diluted EPS of $0.05 and non-GAAP diluted EPS of $0.07 Reports combined cash and investments
IRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results Winter Springs, Florida, February 4, 2021 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only know
Read more →IRMDIRADIMED CORPORATION to Hold 2020 Fourth Quarter Financial Results Conference Call on February 4th
WINTER SPRINGS, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4th. IRADIMED management will host a conference call t
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2020 Financial Results
Reports third quarter 2020 revenue of $7.7 million, GAAP diluted EPS of $0.09 and non-GAAP diluted EPS of $0.11 Reports combined cash and investments of $49.9 million as of September 30, 2020 WINTER SPRINGS, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Com
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2020 Financial Results Reports third quarter 2020 revenue of $7.7 million, GAAP diluted EPS of $0.09 and non-GAAP diluted EPS of $0.11 Reports combined cash and investments o
CORPORATION Announces Third Quarter 2020 Financial Results Winter Springs, Florida, October 30, 2020 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider
Read more →IRMDIRADIMED CORPORATION to Hold 2020 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 third quarter financial results before the market opens on Friday, October 30th. IRADIMED management will host a conference call the
Read more →IRMDE xhibit 99.1 IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results Reports second quarter 2020 revenue of $6.8 million, GAAP diluted EPS of $(0.17) and non-GAAP diluted EPS of $0.05 Reports combined cash
IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results Winter Springs, Florida, July 30, 2020 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known p
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2020 Financial Results
Reports second quarter 2020 revenue of $6.8 million, GAAP diluted EPS of $(0.17) and non-GAAP diluted EPS of $0.05 Reports combined cash and investments of $47.8 million as of June 30, 2020 WINTER SPRINGS, Fla., July 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Compa
Read more →IRMDIRADIMED CORPORATION to Hold 2020 Second Quarter Financial Results Conference Call on July 30th
WINTER SPRINGS, Fla., July 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 second quarter financial results before the market opens on Thursday, July 30th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer
WINTER SPRINGS, Fla., May 29, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s President and Chief Executive Officer after the departure of Leslie McDonnell, wh
Read more →IRMDI R ADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer Winter Springs, Florida
IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer Winter Springs, Florida, May 29, 2020 - IRADIMED Corporation (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company's President and C
Read more →IRMDIRADIMED CORPORATION Announces Issuance of U.S. Patent
WINTER SPRINGS, Fla., May 11, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced the issuance by the U.S. Patent and Trademark Office of a patent that expands on previous claims pertaining to the wireless remote control of IV infusion pumps. The patent
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2020 Financial Results Reports first quarter 2020 revenue of $8.7 million, GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.18 Reports combined cash and investments of
IRADIMED CORPORATION Announces First Quarter 2020 Financial Results Winter Springs, Florida, April 30, 2020 - iRadimed Corporation (the "Company") (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known p
Read more →IRMDIRADIMED CORPORATION to Hold 2020 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 first quarter financial results before the market opens on Thursday, April 30th. iRadimed management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Withdraws 2020 Financial Guidance Due to Uncertainties from the Effects of COVID-19 Expects first quarter 2020 revenue of $8.6 million to $8.7 million Winter Springs, Florida
CORPORATION Withdraws 2020 Financial Guidance Due to Uncertainties from the Effects of COVID-19 Winter Springs, Florida, April 7, 2020 - iRadimed Corporation (NASDAQ: IRMD) announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is wi
Read more →IRMDIRADIMED CORPORATION Announces the Appointment of Lynn Neuhardt as Vice President of Research and Development
WINTER SPRINGS, Fla., March 12, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced the appointment of Lynn Neuhardt as Vice President of Research and Development, effective March 26, 2020. Mr. Neuhardt will report to Leslie McDonnell, President and Chief Execu
Read more →IRMDIRADIMED CORPORATION to Present at the 32nd Annual Roth Conference
WINTER SPRINGS, Fla., March 06, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that Leslie McDonnell, President and Chief Executive Officer, will present at the 32nd Annual Roth Conference in Laguna Niguel, CA. Ms. McDonnell is scheduled to present
Read more →IRMDIRADIMED CORPORATION Announces Retirement of Francis Casey and the Appointment of Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance Winter Springs, Florida
IRADIMED CORPORATION Announces Retirement of Francis Casey and the Appointment of Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance Winter Springs, Florida, February 26, 2020 - iRadimed Corporation (NASDAQ: IRMD) announced the retirement of Franc
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2019 Financial Results Reports fourth quarter 2019 revenue of $10.9 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.30 Renewed CE Mark for patient vital sig
CORPORATION Announces Fourth Quarter 2019 Financial Results Reports fourth quarter 2019 revenue of $10.9 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.30 Renewed CE Mark for patient vital signs monitor and shipped associated backlog during the fourth quar
Read more →IRMDIRADIMED CORPORATION to Hold 2019 Fourth Quarter Financial Results Conference Call on February 6th
WINTER SPRINGS, Fla., Jan. 22, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 fourth quarter financial results before the market opens on Thursday, February 6th. IRADIMED management will host a conference call t
Read more →IRMDIRADIMED CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales Winter Springs, Florida
CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales Winter Springs, Florida, January 7, 2020 - iRadimed Corporation (NASDAQ: IRMD) announced the retirement of Brent Johnson, Executive Vice President of Wor
Read more →IRMDIRADIMED CORPORATION Completes CE Mark Renewal Process For Its MRI Compatible Patient Vital Signs Monitoring System Immediately resumes shipments of patient vital signs monitoring systems into all markets requiring CE Ma
CORPORATION Completes CE Mark Renewal Process For Its MRI Compatible Patient Vital Signs Monitoring System Winter Springs, Florida, December 12, 2019 - iRadimed Corporation (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical dev
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2019 Financial Results Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Updates full-year financial guidance W
IRADIMED CORPORATION Announces Third Quarter 2019 Financial Results Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Updates full-year financial guidance Winter Springs, Florida, October 30, 2019 IRADIMED CORPORAT
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2019 Financial Results
Reports third quarter 2019 revenue of $10.0 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23 Updates full-year financial guidance WINTER SPRINGS, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of inno
Read more →IRMDIRADIMED CORPORATION to Hold 2019 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 16, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 third quarter financial results before the market opens on Wednesday, October 30th. IRADIMED management will host a conference call t
Read more →IRMDI RADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System Winter Springs, Florida
IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System Winter Springs, Florida, October 8, 2019 IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cit
Read more →IRMDIRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System
WINTER SPRINGS, Fla., Oct. 08, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. “The resolution of the warnin
Read more →IRMDIRADIMED CORPORATION to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
WINTER SPRINGS, Fla., Aug. 27, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chief Technology Officer and Chris Scott, Chief Financial Officer, will participate
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2019 Financial Results Reports second quarter 2019 revenue of $9.2 million Reports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20 Updates fu
IRADIMED CORPORATION Announces Second Quarter 2019 Financial Results Reports second quarter 2019 revenue of $9.2 million Reports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20 Updates full year earnings guidance Winter Springs, Florida, July 3
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2019 Financial Results
Reports second quarter 2019 revenue of $9.2 million Reports second quarter 2019 GAAP diluted EPS of $0.17 and non-GAAP diluted EPS of $0.20 Updates full year earnings guidance WINTER SPRINGS, Fla., July 30, 2019 (GLOBE NEWSWIRE) -- iRadimed Corporation (NASDAQ: IRMD), a leader
Read more →IRMDIRADIMED CORPORATION Names Leslie McDonnell as President and Chief Executive Officer
WINTER SPRINGS, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that its Board of Directors unanimously appointed Leslie McDonnell, to succeed Roger Susi as President and Chief Executive Officer. Mr. Susi will step down as President and
Read more →IRMDIRADIMED CORPORATION to Hold 2019 Second Quarter Financial Results Conference Call on July 30th
WINTER SPRINGS, Fla., July 16, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 second quarter financial results before the market opens on Tuesday, July 30th. iRadimed management will host a conference call the s
Read more →IRMDI RADIMED CORPORATION Announces First Quarter 2019 Financial Results Reports first quarter 2019 revenue of $8.4 million Reports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 Winter Spring
IRADIMED CORPORATION Announces First Quarter 2019 Financial Results Reports first quarter 2019 revenue of $8.4 million Reports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 Winter Springs, Florida, April 30, 2019 IRADIMED CORPORATION (NASDAQ:IR
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2019 Financial Results
Reports first quarter 2019 revenue of $8.4 million Reports first quarter 2019 GAAP diluted EPS of $0.15 and non-GAAP diluted EPS of $0.13 WINTER SPRINGS, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- iRadimed Corporation (NASDAQ: IRMD), a leader in the development of innovative magn
Read more →IRMDIRADIMED CORPORATION to Hold 2019 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 16, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 first quarter financial results before the market opens on Tuesday, April 30th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces FDA 510(k) Clearance for Neonatal Pulse Oximetry and Capnography Monitoring Using its MRI-Compatible Patient Vital Signs Monitor
WINTER SPRINGS, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received FDA 510(k) clearance for neonatal use of the pulse oximetry (“SpO2”) and Capnography (“CO2”) monitoring features of its 3880 Magnetic Resonance Imaging (
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results
Reports fourth quarter 2018 revenue of $8.3 million Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16 Announces 2019 full year and first quarter financial guidance WINTER SPRINGS, Fla., Feb. 06, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATIO
Read more →IRMDI RADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results Reports fourth quarter 2018 revenue of $8.3 million Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16 Announces
IRADIMED CORPORATION Announces Fourth Quarter 2018 Financial Results Reports fourth quarter 2018 revenue of $8.3 million Reports fourth quarter 2018 GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.16 Announces 2019 full year and first quarter financial guidance Winte
Read more →IRMDIRADIMED CORPORATION to Hold 2018 Fourth Quarter Financial Results Conference Call on February 6th
WINTER SPRINGS, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2018 fourth quarter financial results before the market opens on Wednesday, February 6th. IRADIMED management will host a conference call
Read more →IRMDIRADIMED CORPORATION Expects Minor Impact to 2019 Revenue After Temporarily Suspending Shipments of MRI Compatible Patient Vital Signs Monitoring Systems in European Markets
Action being taken after CE mark expiration Expects negative impact to full-year 2019 revenue of approximately two percent WINTER SPRINGS, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance i
Read more →IRMDIRAD IME D CORPORATION Expects Minor Impact to 2019 Revenue After Temporarily Suspending Shipments of MRI Compatible Patient Vital Signs Monitoring Systems in European Markets Action being taken after CE mark expiration
IRADIMED CORPORATION Expects Minor Impact to 2019 Revenue After Temporarily Suspending Shipments of MRI Compatible Patient Vital Signs Monitoring Systems in European Markets Action being taken after CE mark expiration Expects negative impact to full-year 2019 revenue of approxi
Read more →IRMDIRADIMED CORPORATION Announces 510(k) Clearance of Invasive Blood Pressure Module for use with its MRI-Compatible Patient Vital Signs Monitor
WINTER SPRINGS, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices, today announced FDA 510(k) clearance of its 3883 MRI-compatible invasive blood pressure module
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2018 Financial Results
Reports third quarter 2018 revenue of $7.6 million Reports third quarter 2018 GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.14 Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings guidance WINTER SPRINGS, Fla., Oct. 30, 2018 (GLOBE NEWSWIRE) -- IRADI
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2018 Financial Results Reports third quarter 2018 revenue of $7.6 million Reports third quarter 2018 GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.14 Increases ful
IRADIMED CORPORATION Announces Third Quarter 2018 Financial Results Reports third quarter 2018 revenue of $7.6 million Reports third quarter 2018 GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.14 Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings gu
Read more →IRMDIRADIMED CORPORATION to Hold 2018 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 16, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2018 third quarter financial results before the market opens on Tuesday, October 30th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces Clearance of MRI Compatible Patient Vital Signs Monitor in Japan
WINTER SPRINGS, Fla., Sept. 11, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices, today announced receipt of regulatory clearance from the Japanese Ministry of Health Labor &
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2018 Financial Results Reports second quarter 2018 revenue of $7.4 million Reports second quarter 2018 GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.14 Increases
IRADIMED CORPORATION Announces Second Quarter 2018 Financial Results Reports second quarter 2018 revenue of $7.4 million Reports second quarter 2018 GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.14 Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2018 Financial Results
Reports second quarter 2018 revenue of $7.4 million Reports second quarter 2018 GAAP diluted EPS of $0.11 and non-GAAP diluted EPS of $0.14 Increases full year 2018 revenue, GAAP and non-GAAP diluted earnings guidance WINTER SPRINGS, Fla., July 31, 2018 (GLOBE NEWSWIRE) -- IRA
Read more →IRMDIRADIMED CORPORATION to Hold 2018 Second Quarter Financial Results Conference Call on July 31st
WINTER SPRINGS, Fla., July 16, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2018 second quarter financial results before the market opens on Tuesday, July 31st. IRADIMED management will host a conference call the sa
Read more →IRMDI RADIMED CORPORATION Announces First Quarter 2018 Financial Results Reports first quarter 2018 revenue of $7.1 million Reports first quarter 2018 GAAP diluted EPS of $0.07 and non-GAAP diluted EPS of $0.10 Increases ful
IRADIMED CORPORATION Announces First Quarter 2018 Financial Results Reports first quarter 2018 revenue of $7.1 million Reports first quarter 2018 GAAP diluted EPS of $0.07 and non-GAAP diluted EPS of $0.10 Increases full year 2018 GAAP and non-GAAP diluted EPS guidance Winter
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2018 Financial Results
Reports first quarter 2018 revenue of $7.1 million Reports first quarter 2018 GAAP diluted EPS of $0.07 and non-GAAP diluted EPS of $0.10 Increases full year 2018 GAAP and non-GAAP diluted EPS guidance WINTER SPRINGS, Fla., April 30, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATI
Read more →IRMDIRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 16, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2018 first quarter financial results before the market opens on Monday, April 30th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED CORPORATION to Present at 30th Annual Roth Conference
WINTER SPRINGS, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Roger Susi, President and Chief Executive Officer, will present at the 30th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled to present on Monday, M
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2017 Financial Results Reports fourth quarter 2017 revenue of $6.7 million Reports fourth quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.10 Records one
IRADIMED CORPORATION Announces Fourth Quarter 2017 Financial Results Reports fourth quarter 2017 revenue of $6.7 million Reports fourth quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.10 Records one-time non-cash charge of $0.5 million related to tax refo
Read more →IRMDIRADIMED CORPORATION to Hold 2017 Fourth Quarter Financial Results Conference Call on February 6th
WINTER SPRINGS, Fla., Jan. 26, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2017 fourth quarter financial results before the market opens on Tuesday, February 6th. IRADIMED management will host a conference call th
Read more →IRMDIRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance Announces Preliminary Full Year and Fourth Quarter 2017 Revenue Announces Fourth Quarter 2017 Financial Results Conference Call Date Winter
IRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance Announces Preliminary Full Year and Fourth Quarter 2017 Revenue Announces Fourth Quarter 2017 Financial Results Conference Call Date Winter Springs, Florida, January 22, 2018 IRADIMED CORPORATION (
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2017 Financial Results Reports third quarter 2017 revenue of $5.7 million Reports third quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.07 Increases ful
IRADIMED CORPORATION Announces Third Quarter 2017 Financial Results Reports third quarter 2017 revenue of $5.7 million Reports third quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.07 Increases full year 2017 non-GAAP diluted EPS guidance Winter Springs,
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2017 Financial Results
Reports third quarter 2017 revenue of $5.7 million Reports third quarter 2017 GAAP diluted EPS of $0.02 and non-GAAP diluted EPS of $0.07 Increases full year 2017 non-GAAP diluted EPS guidance WINTER SPRINGS, Fla., Oct. 30, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDA
Read more →IRMDIRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor Winter Springs, Florida
IRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor Winter Springs, Florida, October 26, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), today announced FDA 510(k) clearance of its 3880 Magnetic Resonance Imaging ( MRI ) compatible patient
Read more →IRMDIRADIMED CORPORATION to Hold 2017 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 16, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2017 third quarter financial results before the market opens on Monday, October 30th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION to Present at Cantor Fitzgerald Global Healthcare Conference
WINTER SPRINGS, Fla., Sept. 18, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Roger Susi, President and Chief Executive Officer and Chris Scott, Chief Financial Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2017 Financial Results Reports second quarter 2017 revenue of $5.5 million Reports second quarter 2017 GAAP diluted EPS of $0.03 and non-GAAP diluted EPS of $0.06 Winter Spr
IRADIMED CORPORATION Announces Second Quarter 2017 Financial Results Reports second quarter 2017 revenue of $5.5 million Reports second quarter 2017 GAAP diluted EPS of $0.03 and non-GAAP diluted EPS of $0.06 Winter Springs, Florida, July 28, 2017 IRADIMED CORPORATION (NASDAQ:
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2017 Financial Results
Reports second quarter 2017 revenue of $5.5 million Reports second quarter 2017 GAAP diluted EPS of $0.03 and non-GAAP diluted EPS of $0.06 WINTER SPRINGS, Fla., July 28, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in the development of innovative magn
Read more →IRMDIRADIMED CORPORATION to Hold 2017 Second Quarter Financial Results Conference Call on July 28th
WINTER SPRINGS, Fla., July 17, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2017 second quarter financial results before the market opens on Friday, July 28th. IRADIMED management will host a conference call the sam
Read more →IRMDI RADIMED CORPORATION Announces First Quarter 2017 Financial Results Reports first quarter 2017 revenue of $5.2 million Reports first quarter 2017 GAAP diluted EPS of $(0.02) and non-GAAP diluted EPS of $0.00 Announces $
IRADIMED CORPORATION Announces First Quarter 2017 Financial Results Reports first quarter 2017 revenue of $5.2 million Reports first quarter 2017 GAAP diluted EPS of $(0.02) and non-GAAP diluted EPS of $0.00 Announces $8 million share repurchase program Winter Springs, Florid
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2017 Financial Result
Reports first quarter 2017 revenue of $5.2 million Reports first quarter 2017 GAAP diluted EPS of $(0.02) and non-GAAP diluted EPS of $0.00 Announces $8 million share repurchase program WINTER SPRINGS, Fla., April 28, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD)
Read more →IRMDIRADIMED CORPORATION to Hold 2017 First Quarter Financial Results Conference Call on April 28th
WINTER SPRINGS, Fla., April 20, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2017 first quarter financial results before the market opens on Friday, April 28th. IRADIMED management will host a conference call the sa
Read more →IRMDIRADIMED Names John McCreery Chief Operating Officer
WINTER SPRINGS, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John McCreery has been appointed Chief Operating Officer, a new position within the Company. Mr. McCreery will have primary responsibility over the regulatory, manufa
Read more →IRMDI RADIMED Names John McCreery Chief Operating Officer Winter Springs, Florida
IRADIMED Names John McCreery Chief Operating Officer Winter Springs, Florida, March 30, 2017 IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John McCreery has been appointed Chief Operating Officer, a new position within the Company. Mr. McCreery will have primary respo
Read more →IRMDIRADIMED CORPORATION to Present at 29th Annual Roth Conference
WINTER SPRINGS, Fla., March 01, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Roger Susi, President and Chief Executive Officer and Chris Scott, Chief Financial Officer, will present at the 29th Annual Roth Conference in Laguna Niguel, CA. Mr.
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2016 Financial Results
Reports fourth quarter 2016 revenue of $6.0 million Reports fourth quarter 2016 GAAP diluted EPS of $0.10 and non-GAAP diluted EPS of $0.11 WINTER SPRINGS, Fla., Feb. 06, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intrav
Read more →IRMDI RADIMED CORPORATION Announces Fourth Quarter 2016 Financial Results Reports fourth quarter 2016 revenue of $6.0 million Reports fourth quarter 2016 GAAP diluted EPS of $0.10 and non-GAAP diluted EPS of $0.11 Winter Spr
IRADIMED CORPORATION Announces Fourth Quarter 2016 Financial Results Reports fourth quarter 2016 revenue of $6.0 million Reports fourth quarter 2016 GAAP diluted EPS of $0.10 and non-GAAP diluted EPS of $0.11 Winter Springs, Florida, February 6, 2017 IRADIMED CORPORATION (NASD
Read more →IRMDIRADIMED CORPORATION to Hold 2016 Fourth Quarter Financial Results Conference Call on February 6th
WINTER SPRINGS, Fla., Jan. 25, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2016 fourth quarter financial results before the market opens on Monday, February 6th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces 2017 Annual and First Quarter Financial Guidance
Announces Preliminary Full Year and Fourth Quarter 2016 Revenue Announces Fourth Quarter 2016 Financial Results Conference Call Date WINTER SPRINGS, Fla., Jan. 18, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (
Read more →IRMDI RADIMED CORPORATION Announces 2017 Annual and First Quarter Financial Guidance Announces Preliminary Full Year and Fourth Quarter 2016 Revenue Announces Fourth Quarter 2016 Financial Results Conference Call Date Winter
IRADIMED CORPORATION Announces 2017 Annual and First Quarter Financial Guidance Announces Preliminary Full Year and Fourth Quarter 2016 Revenue Announces Fourth Quarter 2016 Financial Results Conference Call Date Winter Springs, Florida, January 18, 2017 IRADIMED CORPORATION (
Read more →IRMDIRADIMED CORPORATION Announces First Shipments of Its MRI Compatible Patient Vital Signs Monitor
WINTER SPRINGS, Fla., Jan. 03, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced the first shipments of its MRI compatible patient vital signs monitoring system to international customers. “Shipments of the new 3880 MRI compatible patient vital signs m
Read more →IRMDIRADIMED CORPORATION Receives FDA Clearance for MRI Compatible IV Infusion Pump
WINTER SPRINGS, Fla., Dec. 19, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that it received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its MRidium 3860+ magnetic resonance imaging (“MRI”) compatible IV infusion pump system, inc
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2016 Financial Results
Reports third quarter revenue of $7.7 million Reports third quarter GAAP diluted earnings per share of $0.13 and non-GAAP of $0.14 WINTER SPRINGS, Fla., Oct. 28, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2016 Financial Results Reports third quarter revenue of $7.7 million Reports third quarter GAAP diluted earnings per share of $0.13 and non-GAAP of $0.14 Winter Springs, Flor
IRADIMED CORPORATION Announces Third Quarter 2016 Financial Results Reports third quarter revenue of $7.7 million Reports third quarter GAAP diluted earnings per share of $0.13 and non-GAAP of $0.14 Winter Springs, Florida, October 28, 2016 IRADIMED CORPORATION (NASDAQ:IRMD),
Read more →IRMDIRADIMED CORPORATION to Hold 2016 Third Quarter Financial Results Conference Call on October 28th
WINTER SPRINGS, Fla., Oct. 18, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2016 third quarter financial results before the market opens on Friday, October 28th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED CORPORATION Revises Financial Guidance for the Third Quarter and Full Year 2016
WINTER SPRINGS, Fla., Oct. 04, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today revised its third quarter and full year 2016 financial guidance. The Company now expects revenue for the third quarter 2016 of approximately $7.5 million to $7.6 million, compared t
Read more →IRMDI RADIMED CORPORATION Revises Financial Guidance for the Third Quarter and Full Year 2016 Schedules conference call for 8:30 AM Eastern Time on Tuesday
IRADIMED CORPORATION Revises Financial Guidance for the Third Quarter and Full Year 2016 Schedules conference call for 8:30 AM Eastern Time on Tuesday, October 4, 2016 Winter Springs, Florida, October 4, 2016 IRADIMED CORPORATION (NASDAQ:IRMD), today revised its third quarter a
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2016 Financial Results
Revenue grows 29.7% compared to the same quarter last year Reports second quarter 2016 GAAP diluted EPS of $0.19 and non-GAAP diluted EPS of $0.24 Increases full year 2016 non-GAAP earnings guidance Submits patient vital signs monitor 510(k) application to FDA for review WINT
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2016 Financial Results Revenue grows 29.7% compared to the same quarter last year Reports second quarter 2016 GAAP diluted EPS of $0.19 and non-GAAP diluted EPS of $0.24 Inc
IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results Revenue grows 29.7% compared to the same quarter last year Reports second quarter 2016 GAAP diluted EPS of $0.19 and non-GAAP diluted EPS of $0.24 Increases full year 2016 non-GAAP earnings guidance Submits
Read more →IRMDIRADIMED CORPORATION to Hold 2016 Second Quarter Financial Results Conference Call on July 29th
WINTER SPRINGS, Fla., July 15, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2016 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the sam
Read more →IRMDI RADIMED CORPORATION Announces Appointment of Jonathan Kennedy to its Board of Directors Winter Springs, Florida
IRADIMED CORPORATION Announces Appointment of Jonathan Kennedy to its Board of Directors Winter Springs, Florida, June 28, 2016 IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Jonathan Kennedy has been appointed to the Company s Board of Directors. Mr. Kennedy, 45, cu
Read more →IRMDIRADIMED CORPORATION Announces Appointment of Jonathan Kennedy to its Board of Directors
WINTER SPRINGS, Fla., June 28, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Jonathan Kennedy has been appointed to the Company’s Board of Directors. Mr. Kennedy, 45, currently serves as Senior Vice President and Chief Financial Officer of Nat
Read more →IRMDIRADIMED CORPORATION Announces Election of Roger Susi as Chairman of the Board
WINTER SPRINGS, Fla., June 14, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors voted unanimously to appoint current President and Chief Executive Officer, Roger Susi, as Chairman of the Board. The appointment was effective a
Read more →IRMDIRADIMED CORPORATION Provides Regulatory Update
WINTER SPRINGS, Fla., June 09, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) IRADIMED CORPORATION has received the FDA’s written response to our appeal of their determination that our 510(k) application for the MRidium 3860+ MRI compatible IV infusion pump was not
Read more →IRMDI RADIMED CORPORATION Provides Regulatory Update Provides regulatory update on the status of its MRI compatible IV infusion pump Winter Springs, Florida
IRADIMED CORPORATION Provides Regulatory Update Provides regulatory update on the status of its MRI compatible IV infusion pump Winter Springs, Florida, June 9, 2016 IRADIMED CORPORATION (NASDAQ:IRMD) IRADIMED CORPORATION has received the FDA s written response to our appeal o
Read more →IRMDI RADIMED CORPORATION Announces First Quarter 2016 Financial Results Revenue grows 28.2% compared to the same quarter last year Reports first quarter 2016 non-GAAP diluted EPS of $0.21 Increases full year 2016 non-GAAP e
IRADIMED CORPORATION Announces First Quarter 2016 Financial Results Revenue grows 28.2% compared to the same quarter last year Reports first quarter 2016 non-GAAP diluted EPS of $0.21 Increases full year 2016 non-GAAP earnings guidance Announces second quarter financial guida
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2016 Financial Results
Revenue grows 28.2% compared to the same quarter last year Reports first quarter 2016 non-GAAP diluted EPS of $0.21 Increases full year 2016 non-GAAP earnings guidance Announces second quarter financial guidance WINTER SPRINGS, Fla., April 29, 2016 (GLOBE NEWSWIRE) -- IRADIME
Read more →IRMDI RADIMED CORPORATION Mourns the Death of Board Member, Serge Novovich Winter Springs, Florida
IRADIMED CORPORATION Mourns the Death of Board Member, Serge Novovich Winter Springs, Florida, April 19, 2016 IRADIMED CORPORATION (NASDAQ:IRMD) is mourning the death of Serge Novovich, a member of the Board of Directors (the Board ) and Audit Committee of the Board, who passed
Read more →IRMDIRADIMED CORPORATION Mourns the Death of Board Member, Serge Novovich
WINTER SPRINGS, Fla., April 19, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) is mourning the death of Serge Novovich, a member of the Board of Directors (the “Board”) and Audit Committee of the Board, who passed away on April 15, 2016. Mr. Novovich had a long and s
Read more →IRMDIRADIMED CORPORATION INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating IRadimed Corporation For Potential Breach of Fiduciary Duty
WILMINGTON, Del., April 11, 2016 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against IRadimed Corporation (“IRadimed” or the “Co
Read more →IRMDI RADIMED CORPORATION Provides Regulatory Update and Schedules First Quarter Conference Call Provides regulatory update on the status of its MRI compatible IV infusion pump Schedules first quarter 2016 financial results
IRADIMED CORPORATION Provides Regulatory Update and Schedules First Quarter Conference Call Provides regulatory update on the status of its MRI compatible IV infusion pump Schedules first quarter 2016 financial results conference call Winter Springs, Florida, April 1, 2016 IRA
Read more →IRMDIRADIMED CORPORATION Provides Regulatory Update and Schedules First Quarter Conference Call
Provides regulatory update on the status of its MRI compatible IV infusion pump Schedules first quarter 2016 financial results conference call WINTER SPRINGS, Fla., April 01, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) With regard to IRADIMED CORPORATION’s Nove
Read more →IRMDI RADIMED CORPORATION Announces Changes to its Board of Directors Winter Springs, Florida
IRADIMED CORPORATION Announces Changes to its Board of Directors Winter Springs, Florida, March 29, 2016 IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Anthony Vuoto has been appointed to the company s Board of Directors and that Jim Hawkins, Chairman of the Board will
Read more →IRMDIRADIMED CORPORATION Announces Changes to its Board of Directors
WINTER SPRINGS, Fla., March 29, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Anthony Vuoto has been appointed to the company’s Board of Directors and that Jim Hawkins, Chairman of the Board will not stand for re-election at the company’s upcom
Read more →IRMDIRADIMED CORPORATION to Present at 28th Annual Roth Conference
WINTER SPRINGS, Fla., March 04, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Roger Susi, President and Chief Executive Officer and Chris Scott, Chief Financial Officer, will present at the 28th Annual Roth Conference in Laguna Niguel, CA. Mr.
Read more →IRMDI RADIMED CORPORATION Announces Fourth Quarter 2015 Financial Results Revenue grows 145.5% compared to the same quarter last year Reports fourth quarter 2015 non-GAAP diluted EPS of $0.22 Winter Springs, Florida
IRADIMED CORPORATION Announces Fourth Quarter 2015 Financial Results Revenue grows 145.5% compared to the same quarter last year Reports fourth quarter 2015 non-GAAP diluted EPS of $0.22 Winter Springs, Florida, February 5, 2016 IRADIMED CORPORATION (NASDAQ:IRMD), the only kno
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2015 Financial Results
Revenue grows 145.5% compared to the same quarter last year Reports fourth quarter 2015 non-GAAP diluted EPS of $0.22 WINTER SPRINGS, Fla., Feb. 05, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pu
Read more →IRMDI RADIMED CORPORATION Announces $10 Million Share Repurchase Program Winter Springs, Florida
IRADIMED CORPORATION Announces $10 Million Share Repurchase Program Winter Springs, Florida, January 28, 2016 IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $10 million o
Read more →IRMDIRADIMED CORPORATION Announces $10 Million Share Repurchase Program
WINTER SPRINGS, Fla., Jan. 28, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $10 million of the Company’s common stock through January 28, 2017.
Read more →IRMDIRADIMED CORPORATION to Hold 2015 Fourth Quarter Financial Results Conference Call on February 5th
WINTER SPRINGS, Fla., Jan. 22, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2015 fourth quarter financial results before the market opens on Friday, February 5th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION Announces 2016 Annual and First Quarter Financial Guidance
WINTER SPRINGS, Fla., Jan. 11, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, today announced its
Read more →IRMDI RADIMED CORPORATION Announces 2016 Annual and First Quarter Financial Guidance Announces Fourth Quarter 2015 Revenue Estimate Winter Springs, Florida
IRADIMED CORPORATION Announces 2016 Annual and First Quarter Financial Guidance Announces Fourth Quarter 2015 Revenue Estimate Winter Springs, Florida, January 11, 2016 IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump sy
Read more →IRMDIRADIMED CORPORATION Announces Closing of $29.1 Million Secondary Offering of Common Stock and Exercise of Overallotment Option
WINTER SPRINGS, Fla., Dec. 23, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ:IRMD), today announced that Roger Susi, the President and Chief Executive of the Company (the “Selling Shareholder”) has completed the sale of 1,200,000 shares (including the exer
Read more →IRMDI R ADIMED CORPORATION Announces Pricing of Secondary Offering of Common Stock Winter Springs, Florida
IRADIMED CORPORATION Announces Pricing of Secondary Offering of Common Stock Winter Springs, Florida, December 18, 2015 - iRadimed Corporation (the "Company") (NASDAQ:IRMD), today announced the pricing of an underwritten secondary offering of 1,043,479 shares of its common stock
Read more →IRMDIRADIMED CORPORATION Announces Pricing of Secondary Offering of Common Stock
WINTER SPRINGS, Fla., Dec. 18, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ:IRMD), today announced the pricing of an underwritten secondary offering of 1,043,479 shares of its common stock by Roger Susi, the President and Chief Executive of the Company (t
Read more →IRMDIRADIMED CORPORATION Announces Proposed Secondary Offering of Common Stock
WINTER SPRINGS, Fla., Dec. 17, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (“IV”) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (“MRI”) procedures,
Read more →IRMDIRADIMED CORPORATION Updates Status of 510(k) Submission
WINTER SPRINGS, Fla., Dec. 10, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, provided an update o
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2015 Financial Results
Revenue grows 114.9% compared to the same quarter last year Reports third quarter 2015 non-GAAP diluted EPS of $0.19 Increases annual revenue and non-GAAP earnings guidance WINTER SPRINGS, Fla., Oct. 30, 2015 (GLOBE NEWSWIRE) -- iRadimed Corporation (NASDAQ:IRMD), the only kno
Read more →IRMDI RADIMED CORPORATION Announces Third Quarter 2015 Financial Results Revenue grows 114.9% compared to the same quarter last year Reports third quarter 2015 non-GAAP diluted EPS of $0.19 Increases annual revenue and non-G
IRADIMED CORPORATION Announces Third Quarter 2015 Financial Results Revenue grows 114.9% compared to the same quarter last year Reports third quarter 2015 non-GAAP diluted EPS of $0.19 Increases annual revenue and non-GAAP earnings guidance Winter Springs, Florida, October 30
Read more →IRMDIRADIMED CORPORATION Announces Dismissal of Appeal
WINTER SPRINGS, Fla., Oct. 30, 2015 (GLOBE NEWSWIRE) -- iRadimed Corporation (NASDAQ:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, announced today that
Read more →IRMDIRADIMED CORPORATION to Hold 2015 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 13, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2015 third quarter financial results before the market opens on Friday, October 30th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2015 Financial Results
Revenue grows 62% compared to the same quarter last year Reports second quarter 2015 non-GAAP diluted EPS of $0.16 Increases full year 2015 revenue and non-GAAP earnings guidance Announces third quarter financial guidance WINTER SPRINGS, Fla., July 30, 2015 (GLOBE NEWSWIRE) -
Read more →IRMDI RADIMED CORPORATION Announces Second Quarter 2015 Financial Results Revenue grows 62% compared to the same quarter last year Reports second quarter 2015 non-GAAP diluted EPS of $0.16 Increases full year 2015 revenue an
IRADIMED CORPORATION Announces Second Quarter 2015 Financial Results Revenue grows 62% compared to the same quarter last year Reports second quarter 2015 non-GAAP diluted EPS of $0.16 Increases full year 2015 revenue and non-GAAP earnings guidance Announces third quarter fina
Read more →IRMDIRADIMED CORPORATION to Hold 2015 Second Quarter Financial Results Conference Call on July 30th
WINTER SPRINGS, Fla., July 13, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2015 second quarter financial results before the market opens on Thursday, July 30th. IRADIMED management will host a conference call the s
Read more →IRMDIRADIMED CORPORATION Announces Favorable Court Ruling
WINTER SPRINGS, Fla., May 27, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, announced today that
Read more →IRMDIRADIMED CORPORATION Hosts Governor Rick Scott
WINTER SPRINGS, Fla., May 22, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, hosted Governor Rick
Read more →IRMDIRADIMED CORPORATION Announces First Quarter 2015 Financial Results Reports first quarter 2015 non-GAAP diluted EPS of $0.14 Revenue grows 96.5% compared to the same quarter last year Increases full year 2015 revenue and
IRADIMED CORPORATION Announces First Quarter 2015 Financial Results Reports first quarter 2015 non-GAAP diluted EPS of $0.14 Revenue grows 96.5% compared to the same quarter last year Increases full year 2015 revenue and non-GAAP earnings guidance Announces second quarter fin
Read more →IRMDIRADIMED CORPORATION to Hold 2015 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) announced today that the Company will release its 2015 first quarter financial results before the market opens on Thursday, April 30th. IRADIMED management will host a conference call the
Read more →IRMDIRADIMED CORPORATION to Present at 27th Annual Roth Conference
WINTER SPRINGS, Fla., Feb. 27, 2015 (GLOBE NEWSWIRE) -- iRadimed Corporation (Nasdaq:IRMD), today announced that Roger Susi, President and Chief Executive Officer and Chris Scott, Chief Financial Officer, will present at the 27th Annual Roth Conference in Laguna Niguel, CA. Mr. S
Read more →IRMDIRADIMED CORPORATION Announces Fourth Quarter 2014 Financial Results Reports fourth quarter 2014 non-GAAP diluted EPS of $0.03 Expects full year 2015 revenue growth of 79% to 85% Winter Springs, Florida
IRADIMED CORPORATION Announces Fourth Quarter 2014 Financial Results Reports fourth quarter 2014 non-GAAP diluted EPS of $0.03 Expects full year 2015 revenue growth of 79% to 85% Winter Springs, Florida, February 5, 2015 IRADIMED CORPORATION (NASDAQ:IRMD), the only provider of
Read more →IRMDIRADIMED CORPORATION Resumes Domestic Distribution of DERS Option Winter Springs, Florida
IRADIMED CORPORATION Resumes Domestic Distribution of DERS Option Winter Springs, Florida, January 28, 2015 IRADIMED CORPORATION (NASDAQ:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems for use during magnetic resonance imaging (MRI) procedures, an
Read more →IRMDIRADIMED CORPORATION to Hold 2014 Fourth Quarter Financial Results Conference Call on February 5th
WINTER SPRINGS, Fla., Jan. 21, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) announced today that the Company will release its 2014 fourth quarter financial results before the market opens on Thursday, February 5th. IRADIMED management will host a conference call th
Read more →IRMDI RADIMED CORPORATION Announces 2015 Annual and First Quarter Financial Guidance Announces Fourth Quarter 2014 Revenue Estimate Winter Springs, Florida
IRADIMED CORPORATION Announces 2015 Annual and First Quarter Financial Guidance Announces Fourth Quarter 2014 Revenue Estimate Winter Springs, Florida, January 12, 2015 IRADIMED CORPORATION (NASDAQ:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems
Read more →IRMDIRADIMED CORPORATION Announces 2015 Annual and First Quarter Financial Guidance
Announces Fourth Quarter 2014 Revenue Estimate WINTER SPRINGS, Fla., Jan. 12, 2015 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) proce
Read more →IRMDI RADIMED CORPORATION Resumes Domestic Distribution of Infusion Pumps Winter Springs, Florida
IRADIMED CORPORATION Resumes Domestic Distribution of Infusion Pumps Winter Springs, Florida, December 22, 2014 IRADIMED CORPORATION (NASDAQ:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems for use during magnetic resonance imaging (MRI) procedures
Read more →IRMDIRADIMED CORPORATION Resumes Domestic Distribution of Infusion Pumps
WINTER SPRINGS, Fla., Dec. 22, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems for use during magnetic resonance imaging (MRI) procedures, announced today that it has resumed domestic distributi
Read more →IRMDIRADIMED CORPORATION Files 510(k) Submission for Premarket Notification
WINTER SPRINGS, Fla., Nov. 25, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures, announced today that it has filed a submi
Read more →IRMDIRADIMED CORPORATION Announces Third Quarter 2014 Financial Results Reports revenue growth of 54% year-over-year Reports non-GAAP diluted EPS of $0.03 Reiterates fourth quarter 2014 operating results Winter Springs, Flor
IRADIMED CORPORATION Announces Third Quarter 2014 Financial Results Reports revenue growth of 54% year-over-year Reports non-GAAP diluted EPS of $0.03 Reiterates fourth quarter 2014 operating results Winter Springs, Florida, October 30, 2014 IRADIMED CORPORATION (NASDAQ:IRMD)
Read more →IRMDIRADIMED CORPORATION to Hold 2014 Third Quarter Financial Results Conference Call on October 30th
WINTER SPRINGS, Fla., Oct. 13, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) announced today that the Company will release its 2014 third quarter financial results before the market opens on Thursday, October 30thth. IRADIMED management will host a conference call t
Read more →IRMDIRADIMED CORPORATION Announces Conference Call to Discuss the Status of the Recent FDA Warning Letter
WINTER SPRINGS, Fla., Sept. 15, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) today announced that it will host a conference call on Thursday, September 18, 2014 beginning at 11:00 a.m. Eastern Time to provide an update on the Company's September 2nd press release r
Read more →IRMDIRADIMED CORPORATION Announces Receipt of FDA Warning Letter
WINTER SPRINGS, Fla., Sept. 2, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) today announced that it received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's facility that took place in April 2014. The C
Read more →IRMDDepartment of Health and Human Services Food and Drug Administration Florida District 555 Winderley Place, Suite 200 Maitland, Florida 32751 Telephone: 407-475-4700 Fax: 407-475-4770 VIA UPS NEXT DAY AIR w/ DELIVERY CONF
Department of Health and Human Services Food and Drug Administration Florida District 555 Winderley Place, Suite 200 Maitland, Florida 32751 Telephone: 407-475-4700 Fax: 407-475-4770 VIA UPS NEXT DAY AIR w/ DELIVERY CONFIRMATION Iradimed Corporation 7457 Aloma Ave, Suite 201
Read more →IRMDIRADIMED CORPORATION Announces Second Quarter 2014 Financial Results Reports revenue growth of 69% year-over-year Reports non-GAAP diluted EPS of $0.13, a 79% increase over last year Issues full year 2014 revenue guidanc
IRADIMED CORPORATION Announces Second Quarter 2014 Financial Results Reports revenue growth of 69% year-over-year Reports non-GAAP diluted EPS of $0.13, a 79% increase over last year Issues full year 2014 revenue guidance of $18.0 million to $18.2 million Closes on IPO and co
Read more →IRMDIRADIMED CORPORATION to Hold 2014 Second Quarter Financial Results Conference Call on August 12th
WINTER SPRINGS, Fla., Aug. 1, 2014 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (Nasdaq:IRMD) announced today that the Company will release its 2014 second quarter financial results before the market opens on Tuesday, August 12th. IRADIMED management will host a conference call the s
Read more →Competitive Position
How IRMD ranks across every disease it competes inCompetitive Position is a premium feature
See how IRMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial